{"title":"使用 99mTc-NM-02 纳米抗体检测乳腺癌患者的 HER2 表达：一项非随机、非盲法临床试验。","authors":"Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao","doi":"10.1186/s13058-024-01803-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><sup>99m</sup>Tc radiolabeled nanobody NM-02 (<sup>99m</sup>Tc-NM-02) is a novel single photon emission computed tomography (SPECT) probe with a high affinity and specificity for human epidermal growth factor receptor 2 (HER2). In this study, a clinical imaging trial was conducted to investigate the relationship between <sup>99m</sup>Tc-NM-02 uptake and HER2 expression in patients with breast cancer.</p><p><strong>Methods: </strong>Thirty patients with pathologically confirmed breast cancer were recruited and imaged with both <sup>99m</sup>Tc-NM-02 SPECT/computed tomography (CT) and <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography (PET)/CT. According to the treatment conditions before recruitment, patients were divided into two groups, the newly diagnosed group (n = 24) and the treated group (n = 6). The maximal standard uptake value (SUV<sub>max</sub>) of <sup>18</sup>F-FDG and SUV<sub>max</sub> and mean SUV (SUV<sub>mean</sub>) of <sup>99m</sup>Tc-NM-02 in the lesions were determined to analyze the relationship with HER2 expression.</p><p><strong>Results: </strong>No meaningful relationship was observed between <sup>18</sup>F-FDG uptake and HER2 expression in 30 patients with breast cancer. <sup>99m</sup>Tc-NM-02 uptake was positively correlated with HER2 expression in the newly diagnosed group, but no correlation was observed in the treated group. <sup>99m</sup>Tc-NM-02 uptake in HER2-positive lesions was lower in those with effective HER2-targeted therapy compared with the newly diagnosed group. <sup>99m</sup>Tc-NM-02 SPECT/CT detected brain and bone metastases of breast cancer with a different imaging pattern from <sup>18</sup>F-FDG PET/CT. <sup>99m</sup>Tc-NM-02 showed no non-specific uptake in inflamed tissues and revealed intra- and intertumoral HER2 heterogeneity by SPECT/CT imaging in 9 of the 30 patients with breast cancer.</p><p><strong>Conclusions: </strong><sup>99m</sup>Tc-NM-02 SPECT/CT has the potential for visualizing whole-body HER2 overexpression in untreated patients, making it a promising method for HER2 assessment in patients with breast cancer.</p><p><strong>Trial registration: </strong>NCT04674722, Date of registration: December 19, 2020.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"40"},"PeriodicalIF":5.6000,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924314/pdf/","citationCount":"0","resultStr":"{\"title\":\"Detection of HER2 expression using <sup>99m</sup>Tc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.\",\"authors\":\"Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao\",\"doi\":\"10.1186/s13058-024-01803-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong><sup>99m</sup>Tc radiolabeled nanobody NM-02 (<sup>99m</sup>Tc-NM-02) is a novel single photon emission computed tomography (SPECT) probe with a high affinity and specificity for human epidermal growth factor receptor 2 (HER2). In this study, a clinical imaging trial was conducted to investigate the relationship between <sup>99m</sup>Tc-NM-02 uptake and HER2 expression in patients with breast cancer.</p><p><strong>Methods: </strong>Thirty patients with pathologically confirmed breast cancer were recruited and imaged with both <sup>99m</sup>Tc-NM-02 SPECT/computed tomography (CT) and <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography (PET)/CT. According to the treatment conditions before recruitment, patients were divided into two groups, the newly diagnosed group (n = 24) and the treated group (n = 6). The maximal standard uptake value (SUV<sub>max</sub>) of <sup>18</sup>F-FDG and SUV<sub>max</sub> and mean SUV (SUV<sub>mean</sub>) of <sup>99m</sup>Tc-NM-02 in the lesions were determined to analyze the relationship with HER2 expression.</p><p><strong>Results: </strong>No meaningful relationship was observed between <sup>18</sup>F-FDG uptake and HER2 expression in 30 patients with breast cancer. <sup>99m</sup>Tc-NM-02 uptake was positively correlated with HER2 expression in the newly diagnosed group, but no correlation was observed in the treated group. <sup>99m</sup>Tc-NM-02 uptake in HER2-positive lesions was lower in those with effective HER2-targeted therapy compared with the newly diagnosed group. <sup>99m</sup>Tc-NM-02 SPECT/CT detected brain and bone metastases of breast cancer with a different imaging pattern from <sup>18</sup>F-FDG PET/CT. <sup>99m</sup>Tc-NM-02 showed no non-specific uptake in inflamed tissues and revealed intra- and intertumoral HER2 heterogeneity by SPECT/CT imaging in 9 of the 30 patients with breast cancer.</p><p><strong>Conclusions: </strong><sup>99m</sup>Tc-NM-02 SPECT/CT has the potential for visualizing whole-body HER2 overexpression in untreated patients, making it a promising method for HER2 assessment in patients with breast cancer.</p><p><strong>Trial registration: </strong>NCT04674722, Date of registration: December 19, 2020.</p>\",\"PeriodicalId\":49227,\"journal\":{\"name\":\"Breast Cancer Research\",\"volume\":\"26 1\",\"pages\":\"40\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2024-03-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924314/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13058-024-01803-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13058-024-01803-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.
Background: 99mTc radiolabeled nanobody NM-02 (99mTc-NM-02) is a novel single photon emission computed tomography (SPECT) probe with a high affinity and specificity for human epidermal growth factor receptor 2 (HER2). In this study, a clinical imaging trial was conducted to investigate the relationship between 99mTc-NM-02 uptake and HER2 expression in patients with breast cancer.
Methods: Thirty patients with pathologically confirmed breast cancer were recruited and imaged with both 99mTc-NM-02 SPECT/computed tomography (CT) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT. According to the treatment conditions before recruitment, patients were divided into two groups, the newly diagnosed group (n = 24) and the treated group (n = 6). The maximal standard uptake value (SUVmax) of 18F-FDG and SUVmax and mean SUV (SUVmean) of 99mTc-NM-02 in the lesions were determined to analyze the relationship with HER2 expression.
Results: No meaningful relationship was observed between 18F-FDG uptake and HER2 expression in 30 patients with breast cancer. 99mTc-NM-02 uptake was positively correlated with HER2 expression in the newly diagnosed group, but no correlation was observed in the treated group. 99mTc-NM-02 uptake in HER2-positive lesions was lower in those with effective HER2-targeted therapy compared with the newly diagnosed group. 99mTc-NM-02 SPECT/CT detected brain and bone metastases of breast cancer with a different imaging pattern from 18F-FDG PET/CT. 99mTc-NM-02 showed no non-specific uptake in inflamed tissues and revealed intra- and intertumoral HER2 heterogeneity by SPECT/CT imaging in 9 of the 30 patients with breast cancer.
Conclusions: 99mTc-NM-02 SPECT/CT has the potential for visualizing whole-body HER2 overexpression in untreated patients, making it a promising method for HER2 assessment in patients with breast cancer.
Trial registration: NCT04674722, Date of registration: December 19, 2020.
期刊介绍：
Breast Cancer Research, an international, peer-reviewed online journal, publishes original research, reviews, editorials, and reports. It features open-access research articles of exceptional interest across all areas of biology and medicine relevant to breast cancer. This includes normal mammary gland biology, with a special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal covers preclinical, translational, and clinical studies with a biological basis, including Phase I and Phase II trials.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
